Loading...
NPI 1043835143 · Oklahoma City, OK · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Qitek Labs Of Oklahoma LLC is a clinical medical laboratory provider located in Oklahoma City, Oklahoma. This profile covers 44 Medicare and 13 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Qitek Labs Of Oklahoma LLC |
| Address | 3636 Nw 63rd St Ste C |
| City | Oklahoma City |
| State | OK |
| ZIP | 73116 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 15, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.2M |
| Medicaid | $10.1K |
QITEK LABS OF OKLAHOMA LLC is operating as a high-volume clinical molecular laboratory focused on amplified nucleic acid probe testing: the top Medicare revenue drivers are codes for amplified probe techniques such as 87798, 87801, and 87481, and the code descriptions indicate routine testing for multiple infectious agents (including multiplex panels) and organism-specific nucleic acid detection. This mix is consistent with a lab that processes large volumes of molecular infectious disease diagnostics rather than low-complexity chemistry or point-of-care testing.
Medicare revenue concentration is heavily skewed toward a very small set of tests: the precomputed top 3 Medicare codes account for 80.5% of the provider’s total Medicare revenue, with 87798 alone representing $2.7M (43.8% of Medicare revenue). This indicates the business is highly dependent on a few molecular assay categories for the bulk of its Medicare income.
By payer scale, the provider is effectively Medicare-dominated: total Medicare revenue is $6.2M versus total Medicaid revenue of $10.1K, indicating Medicare constitutes the overwhelming share of lifetime billed revenue and QITEK is not materially active on Medicaid in financial terms. Analysts should treat the entity as a Medicare-centered lab when assessing market footprint and exposure.
On national competitive standing for key Medicare codes, QITEK appears as a major volume outlier: 87801 ranks #8 of 561 providers nationally (99th percentile; extreme outlier) and 87481 ranks #13 of 1117 providers nationally (99th percentile; extreme outlier), while 87798 ranks #26 of 1319 providers (98th percentile; notably above typical national volume). These rank/percentile placements show QITEK is among the highest-volume national providers for multiple amplified probe assays.
Medicaid activity is minimal and more distributed across similar molecular codes at low unit payments: the top 3 Medicaid codes mirror Medicare code types (87798, 87801, and 87640) but together the top 3 Medicaid codes account for 65.7% of its small Medicaid revenue base. The Medicaid payments per claim are substantially lower in the state data (for example, 87798 at $5 average paid/claim and 87801 at $2), which compresses total Medicaid revenue despite nontrivial claim counts.
Within-state competitive positioning on Medicaid is middling for its leading codes: 87798 ranks #11 of 33 providers in-state (69th percentile) and 87801 ranks #4 of 18 providers (82nd percentile), indicating QITEK is a notable but not dominant in-state participant for these specific Medicaid-paid molecular tests. Given the small Medicaid revenue total ($10.1K), the in-state ranks reflect activity but limited financial impact.
The provider’s service-line footprint includes a broad array of organism-specific amplified probe tests beyond the top three, evidenced on Medicare by multiple codes with notable national rank (87651, 87500, 87640, 87641 all at high percentiles). This pattern suggests the lab operates a panel of nucleic acid amplification assays covering respiratory, sexually transmitted, and antimicrobial-resistance targets and likely supports high-throughput specimen processing.
Tenure is moderate: the NPI was enumerated on 2020-06-15 (approximately 6 years ago), indicating the lab has established several years of billing history to accumulate the observed Medicare volumes. That timeline supports the interpretation that QITEK scaled its molecular testing volumes within a relatively short operational window.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
44 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 79,330 | $30 | $2.7M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 17,930 | $70 | $1.2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 30,250 | $30 | $1M |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 6,060 | $30 | $205.9K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 6,060 | $30 | $205.9K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 6,040 | $30 | $205.3K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 6,030 | $30 | $205.2K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 5,980 | $30 | $203.3K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 3,120 | $30 | $106.1K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 10,840 | $1 | $10.8K |
Showing 1–10 of 44
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 800 | $10 | $4K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 750 | $1 | $1.5K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 770 | $1 | $770 |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 770 | $1 | $770 |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 730 | $1 | $730 |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 610 | $1 | $610 |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 580 | $1 | $580 |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 580 | $1 | $580 |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 60 | $0 | $0 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 30 | $0 | $0 |
Showing 1–10 of 13
How this provider's Medicaid billing volume and revenue compare to other Oklahoma providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Oklahoma median
13 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 4 | 20 | 60 | $60 | $404.2K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 70 | 80 | 280 | $20 | $72.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 147 | 150 | 1,280 | $10 | $67.8K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 185 | 190 | 1,420 | $10 | $47.2K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 11 | 30 | 260 | $30 | $40K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 7 | 20 | 310 | $30 | $35.4K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 20 | 80 | 200 | $30 | $19.8K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 309 | 420 | 270 | $10 | $12.9K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 4 | 10 | 330 | $10 | $7.5K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 5 | 20 | 130 | $20 | $6.3K |
Showing 1–10 of 13
Other providers in the same ZIP code as Qitek Labs Of Oklahoma LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.